Literature DB >> 12424571

Acute onset of nephrotic syndrome during interferon-alpha retreatment for chronic active hepatitis C.

Satoshi Nishimura1, Hideaki Miura, Haruki Yamada, Toshio Shinoda, Shigehiro Kitamura, Yasusada Miura.   

Abstract

A 57-year-old woman was scheduled to receive recombinant interferon-alpha retreatment for chronic active hepatitis C. During the course of therapy, the patient showed rapid onset of oliguria, dizziness, edema, and a pre-shock state. She was subsequently admitted to hospital and was diagnosed as having nephrotic syndrome. After admission, albumin-dominant proteinuria persisted despite the discontinuation of interferon therapy. Light microscopy of a renal needle biopsy specimen showed interstitial lymphoid cell infiltration, but no marked changes of the glomeruli and no staining for immunoglobulin or complement. Electron microscopy showed diffuse effacement of the glomerular epithelial foot processes, leading to a diagnosis of minimal change nephrotic syndrome with interstitial nephritis. Proteinuria resolved after the initiation of oral prednisolone therapy (1 mg/kg per day). The number of patients with chronic hepatitis C requiring interferon retreatment is increasing rapidly. We herein report this rare case of acute onset of nephrotic syndrome during interferon-alpha retreatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12424571     DOI: 10.1007/s005350200141

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  6 in total

1.  Renal adverse effects of interferon-alpha.

Authors:  Slobodan Jankovic
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis.

Authors:  Glen S Markowitz; Samih H Nasr; M Barry Stokes; Vivette D D'Agati
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 8.237

Review 3.  De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).

Authors:  Fabrizio Fabrizi; Alessio Aghemo; Gabriella Moroni; Patrizia Passerini; Roberta D'Ambrosio; Paul Martin; Piergiorgio Messa
Journal:  Dig Dis Sci       Date:  2013-12-08       Impact factor: 3.487

4.  Development of latent Interferon alpha 2b as a safe therapeutic for treatment of Hepatitis C virus infection.

Authors:  Iram Gull; Muhammad Shahbaz Aslam; Imran Tipu; Roohi Mushtaq; Tehseen Zamir Ali; Muhammad Amin Athar
Journal:  Sci Rep       Date:  2019-07-26       Impact factor: 4.379

Review 5.  Side effects of cytokines approved for therapy.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606

6.  Broad spectrum of interferon-related nephropathies-glomerulonephritis, systemic lupus erythematosus-like syndrome and thrombotic microangiopathy: A case report and review of literature.

Authors:  Iacopo Gianassi; Marco Allinovi; Leonardo Caroti; Lino Calogero Cirami
Journal:  World J Nephrol       Date:  2019-11-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.